CN115551487A - 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物 - Google Patents

使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物 Download PDF

Info

Publication number
CN115551487A
CN115551487A CN202180034458.7A CN202180034458A CN115551487A CN 115551487 A CN115551487 A CN 115551487A CN 202180034458 A CN202180034458 A CN 202180034458A CN 115551487 A CN115551487 A CN 115551487A
Authority
CN
China
Prior art keywords
subject
certain embodiments
glu
mtor inhibitor
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034458.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿卡尔
M·施韦卡特
M·朱比利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN115551487A publication Critical patent/CN115551487A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180034458.7A 2020-05-15 2021-05-14 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物 Pending CN115551487A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025955P 2020-05-15 2020-05-15
US63/025,955 2020-05-15
PCT/US2021/032434 WO2021231851A1 (en) 2020-05-15 2021-05-14 Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors

Publications (1)

Publication Number Publication Date
CN115551487A true CN115551487A (zh) 2022-12-30

Family

ID=78525025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034458.7A Pending CN115551487A (zh) 2020-05-15 2021-05-14 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物

Country Status (11)

Country Link
US (1) US20230210827A1 (https=)
EP (2) EP4149441A4 (https=)
JP (1) JP2023526590A (https=)
KR (1) KR20230010641A (https=)
CN (1) CN115551487A (https=)
AU (1) AU2021273065A1 (https=)
BR (1) BR112022022830A2 (https=)
CA (1) CA3177632A1 (https=)
IL (1) IL298156A (https=)
MX (1) MX2022014080A (https=)
WO (1) WO2021231851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
IL258574B2 (en) * 2015-11-11 2025-01-01 Novartis Ag Uses of myostatin antagonists, combinations containing them and their uses
PL3490582T3 (pl) * 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
HRP20241477T1 (hr) * 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease

Also Published As

Publication number Publication date
KR20230010641A (ko) 2023-01-19
US20230210827A1 (en) 2023-07-06
EP4149441A1 (en) 2023-03-22
BR112022022830A2 (pt) 2022-12-13
AU2021273065A1 (en) 2022-12-15
WO2021231851A1 (en) 2021-11-18
MX2022014080A (es) 2022-12-07
EP4149441A4 (en) 2024-03-13
JP2023526590A (ja) 2023-06-22
IL298156A (en) 2023-01-01
EP4649961A3 (en) 2026-02-25
CA3177632A1 (en) 2021-11-18
EP4649961A2 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
JP7315487B2 (ja) 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
JP6796626B2 (ja) 無効赤血球生成を処置するための方法および組成物
CN107135646B (zh) 用于治疗溃疡的方法和组合物
TWI472336B (zh) 使用ｇｄｆ阱以增加紅血球水平
US20190049469A1 (en) Biomarker for use in treating anemia
US20150266950A1 (en) Methods for treating anemia
CN114675039A (zh) 激活素-actrii拮抗剂及用于治疗贫血症的用途
CN115551487A (zh) 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物
CN115427056A (zh) 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
EA049358B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ АНЕМИИ С ПРИМЕНЕНИЕМ ЛИГАНДОВ-ЛОВУШЕК ActRIIB И ИНГИБИТОРОВ mTOR
HK40077393A (en) Methods for treating anemia using an actriib ligand trap and fedratinib
AU2015202035B2 (en) Use of GDF traps to increase red blood cell levels

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination